Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab

Exp Cell Res. 2011 May 15;317(9):1255-60. doi: 10.1016/j.yexcr.2011.03.010. Epub 2011 Mar 16.

Abstract

Severe side effects and few long-term remissions frequently limit the treatment of advanced malignant diseases. Bispecific antibodies are currently emerging as a new option for the treatment of malignant diseases, which can potentially engage all cytotoxic T cells of a patient for tumor cell lysis. Blinatumomab, a bispecific single-chain BiTE antibody construct with dual specificity for CD19 and CD3, is a front runner of this antibody class. We here summarize the current state of development of blinatumomab for the treatment of patients with B-cell non-Hodgkin's lymphoma (NHL) and B-precursor acute lymphocytic leukemia (ALL). High response rates and durable remissions are observed in first clinical trials, indicating that T cells can be potently redirected for efficient and lasting elimination of malignant cells.

Publication types

  • Review

MeSH terms

  • Antibodies, Bispecific / immunology
  • Antibodies, Bispecific / therapeutic use*
  • Clinical Trials as Topic
  • Humans
  • Immunomodulation*
  • Leukemia, Lymphoid / immunology*
  • Leukemia, Lymphoid / therapy*
  • Lymphoma, B-Cell / immunology*
  • Lymphoma, B-Cell / therapy*
  • T-Lymphocytes / immunology*

Substances

  • Antibodies, Bispecific
  • blinatumomab